Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone813-3278-2306
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.88 billion
Profitability
Miscellaneous
Employees49,578
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions
What is Takeda Pharmaceutical's stock symbol?
Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
How were Takeda Pharmaceutical's earnings last quarter?
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced its earnings results on Wednesday, July, 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $7.73 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.23% and a net margin of 4.01%. View Takeda Pharmaceutical's Earnings History.
When is Takeda Pharmaceutical's next earnings date?
What is the consensus analysts' recommendation for Takeda Pharmaceutical?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Takeda Pharmaceutical.
Has Takeda Pharmaceutical been receiving favorable news coverage?
Headlines about TAK stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Takeda Pharmaceutical earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Takeda Pharmaceutical.
Who are some of Takeda Pharmaceutical's key competitors?
Some companies that are related to Takeda Pharmaceutical include Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY), Zoetis (ZTS) and Allergan (AGN).
What other stocks do shareholders of Takeda Pharmaceutical own?
Who are Takeda Pharmaceutical's key executives?
Takeda Pharmaceutical's management team includes the folowing people:
- Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
- Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
- Dr. Seigo Izumo M.D., Chair of Management Board
- Mr. Costa Saroukos, Chief Financial Officer (Age 48)
- Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)
Who are Takeda Pharmaceutical's major shareholders?
Takeda Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%), Heritage Investors Management Corp (0.01%), Regentatlantic Capital LLC (0.00%), World Asset Management Inc (0.00%), DNB Asset Management AS (0.00%) and Pacer Advisors Inc. (0.00%).
Which major investors are selling Takeda Pharmaceutical stock?
TAK stock was sold by a variety of institutional investors in the last quarter, including Regentatlantic Capital LLC, DNB Asset Management AS, World Asset Management Inc and CLARET ASSET MANAGEMENT Corp.
Which major investors are buying Takeda Pharmaceutical stock?
TAK stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Heritage Investors Management Corp, Signaturefd LLC, Pacer Advisors Inc. and Stephens Inc. AR.
How do I buy shares of Takeda Pharmaceutical?
Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Takeda Pharmaceutical's stock price today?
One share of TAK stock can currently be purchased for approximately $17.55.
How big of a company is Takeda Pharmaceutical?
Takeda Pharmaceutical has a market capitalization of $54.71 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe.View Additional Information About Takeda Pharmaceutical.
What is Takeda Pharmaceutical's official website?
How can I contact Takeda Pharmaceutical?
Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306.
MarketBeat Community Rating for Takeda Pharmaceutical (NYSE TAK)
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TAK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days.
